Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM

MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

“People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In MAPLE-HCM, MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden and cardiac biomarkers compared to metoprolol. MYQORZO is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its U.S. label, providing cardiologists and patients important information to inform treatment decisions.”

MYQORZO was approved by the FDA in December 2025 for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms based on the results from SEQUOIA-HCM, the pivotal, randomized, placebo-controlled, Phase 3 clinical trial of MYQORZO in patients with oHCM on background therapy. It is also approved for the treatment of patients with oHCM in China, European Union, United Kingdom and Canada.

Read the Full Release

Publish date

November 16, 2026